Trelegy Ellipta (Inhaletion powder)

Trelegy Ellipta is a combination inhalation powder designed for the once-daily maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma in adults. It contains three active ingredients: Fluticasone furoate, a corticosteroid that reduces inflammation; Umeclidinium, a long-acting muscarinic antagonist (LAMA) that relaxes airway muscles; and Vilanterol, a long-acting beta-agonist (LABA) that opens the airways. Together, these ingredients help improve lung function, reduce symptoms, and enhance overall quality of life for patients with COPD and asthma.

Indications:

• Maintenance treatment of COPD in adults.
• Maintenance treatment of asthma in adults and children aged 12 years and older.

Dosage and Administration:

• The recommended dosage for adults is one inhalation of Trelegy Ellipta (containing 100mcg of Fluticasone furoate, 62.5mcg of Umeclidinium, and 25mcg of Vilanterol) once daily, at the same time each day.
• Inhalation technique should be reviewed regularly to ensure optimal drug delivery.

Contraindications:

• Known hypersensitivity to any of the active ingredients or excipients in the formulation.
• Not for the treatment of acute bronchospasm or as a rescue inhaler.

Precautions:

• Caution is advised in patients with a history of cardiovascular disease, hypertension, or seizures.
• Regular monitoring of lung function and symptom control is essential, particularly in patients transitioning from oral or systemic corticosteroids.

Side Effects:
Common side effects may include:

• Oral thrush (candidiasis)
• Hoarseness
• Headache
• Sore throat
• Cough

Serious side effects may include:

• Signs of hypersensitivity (e.g., rash, itching, swelling)
• Worsening of asthma or COPD symptoms
• Pneumonia (especially in COPD patients)

Drug Interactions:
Trelegy Ellipta may interact with other medications, particularly those that affect cytochrome P450 enzymes, which can alter the effectiveness of the active ingredients. Patients should inform their healthcare provider of all medications they are taking.

Storage:

• Store the inhaler at room temperature (15-30°C or 59-86°F), protected from moisture and direct sunlight.
• Keep out of reach of children and do not freeze.

Packaging:
Trelegy Ellipta is available in a dry powder inhaler (DPI) format, designed for easy and accurate dosing with a specified number of doses per inhaler.